Early Detection Research Network

Rahman 9-marker MALDI MS panel for Lung Cancer

Aliases:
This biomarker is also known as:

    Description…

    This panel was derived from the proteomic analysis of bronchial lesions that could predict the diagnosis of lung cancer. Nine matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) mass to charge ratio features were selected to build a prediction model diagnostic of lung cancer. One signature was not able to be associated with a particular protein. The remaining eight signatures are derived from: Thymosin beta-4 (TMSB4X), Macrophage migration inhibitory factor (MIF), Des-ubiquitin (Ubiquitin-Gly-Gly), Ubiquitin, Acyl-coA binding protein (ACBP, also known as DBI), Cystatin A (CSTA), and Cytochrome c.

    Datasets

    There are no datasets associated with this biomarker.

    Attributes
    QA State: Curated
    Short Name:
    HGNC Name:

    Panel Details

    The following organs have data associated with this biomarker…

    Attributes

    Phase: Two
    QA State: Curated

    Overview

    Determining the probability of having lung cancer based on a novel proteomic signature of bronchial lesions may have important clinical implications. This signature may facilitate the diagnosis of lung cancer and the monitoring of high-risk individuals for lung cancer in surveillance and chemoprevention trials.

    Performance Comment

    This panel provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions.

    This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

    No other associated resources found.